Date: 2015-01-29
Type of information: Private placement
Company: Verastem (USA - CA)
Investors:
Amount: $50.9 million
Funding type: private placement
Planned used:
Others: * On January 29, 2015, Verastem announced the closing of the public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares of common stock, at the public offering price of $6.50 per share. The exercise of the underwriters’ option brought the total number of shares of common stock sold by Verastem to 8,337,500 shares and increased the total gross proceeds raised in this offering to $54.2 million, before deducting the underwriting discounts and commissions. The net proceeds to Verastem from this offering were $50.9 million.
* On January 20, 2015, Verastem announced that it intends to offer and sell $40 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering are to be sold by Verastem. Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers and Guggenheim Securities, LLC and Oppenheimer & Co. Inc. are acting as co-lead managers in the offering.
Therapeutic area: Cancer - Oncology
